better trial - better cure

Match Patient Populations Most Likely to Respond to Your Drug.

old drug new life

Extend Patent Protection with Drug / Biomarker Combination.

Better Biomarkers. Better Cure.



Martina Schad

CoFounder - CEO

Jim Kallarackal

CoFounder - CTO

Dorian Bevec

Medical and Scientific Advisor

Tim Rödiger

Economic Healthcare Advisor


OakLabs Develops Novel Biomarkers from Existing Clinical Samples and Data.

  • Interested in an accurate biomarker specifically designed for your drug that creates new IP and maximizes patent protection?
  • Want to make sure that a novel biomarker will be a feasible fall back option in case your drug requires one?
  • Aim at early acquisition of data that prove a significant added value for your drug?
  • Want to find out what benefits to expect from a novel AI-developed biomarker?
  • Unsure if your mode of action biomarker is sufficiently reliable for patient selection?

Contact Us

If you have any questions or would like to receive more information, please feel free to contact us at any time.

OakLabs, One Broadway, Cambridge, MA 02142, USA

+1 617 - 863 9616

Get in touch